[go: up one dir, main page]

PE20190801A1 - Compuestos terapeuticamente activos y sus metodos de uso - Google Patents

Compuestos terapeuticamente activos y sus metodos de uso

Info

Publication number
PE20190801A1
PE20190801A1 PE2019000472A PE2019000472A PE20190801A1 PE 20190801 A1 PE20190801 A1 PE 20190801A1 PE 2019000472 A PE2019000472 A PE 2019000472A PE 2019000472 A PE2019000472 A PE 2019000472A PE 20190801 A1 PE20190801 A1 PE 20190801A1
Authority
PE
Peru
Prior art keywords
compound
formula
optionally substituted
methods
active compounds
Prior art date
Application number
PE2019000472A
Other languages
English (en)
Inventor
Rene M Lemieux
Janeta Popovici-Muller
Jeremy Travins
Zhenwei Cai
Dawei Cui
Ding Zhou
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48797706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20190801(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of PE20190801A1 publication Critical patent/PE20190801A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Referido a un metodo para preparar un compuesto de formula (A) o su sal farmaceuticamente aceptable; en donde, R1 es carbociclico C4-C6 opcionalmente sustituido; cada R2 y R3 se selecciona independientemente de arilo o heteroarilo, cada uno opcionalmente sustituido; R4 es arilo o heteroarilo, cada uno opcionalmente sustituido; n es 1 o 2; y X es -CH2-, O, -NH-, -CH(OH)- o -CH(F)-; donde el metodo comprende hacer reaccionar un compuesto de formula (B) con R4-Bren condiciones Buchwald para proporcionar el compuesto de formula (A). Tambien se refiere a un metodo para tratar un cancer caracterizado por la presencia de un alelo mutante en la enzima isoscitrato deshidrogenasa 1 (IDH1)
PE2019000472A 2012-01-19 2013-01-21 Compuestos terapeuticamente activos y sus metodos de uso PE20190801A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012070601 2012-01-19
PCT/CN2013/000068 WO2013107291A1 (en) 2012-01-19 2013-01-21 Therapeutically active compounds and their methods of use

Publications (1)

Publication Number Publication Date
PE20190801A1 true PE20190801A1 (es) 2019-06-10

Family

ID=48797706

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019000472A PE20190801A1 (es) 2012-01-19 2013-01-21 Compuestos terapeuticamente activos y sus metodos de uso
PE2014001128A PE20141824A1 (es) 2012-01-19 2013-01-21 Compuestos terapeuticamente activos y sus metodos de uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2014001128A PE20141824A1 (es) 2012-01-19 2013-01-21 Compuestos terapeuticamente activos y sus metodos de uso

Country Status (42)

Country Link
US (7) US9474779B2 (es)
EP (3) EP2804851B1 (es)
JP (4) JP6313714B2 (es)
KR (3) KR102144739B1 (es)
CN (2) CN104136411B (es)
AR (2) AR089768A1 (es)
AU (3) AU2013211436B2 (es)
BR (1) BR112014017840B1 (es)
CA (2) CA3077245A1 (es)
CL (1) CL2014001891A1 (es)
CO (1) CO7010834A2 (es)
CR (2) CR20170097A (es)
CY (3) CY1120651T1 (es)
DK (2) DK3447052T3 (es)
EA (2) EA035662B1 (es)
EC (1) ECSP14014544A (es)
ES (2) ES2685746T3 (es)
FI (1) FIC20230031I1 (es)
FR (1) FR23C1031I2 (es)
HR (2) HRP20181199T1 (es)
HU (3) HUE039110T2 (es)
IL (3) IL233683B (es)
IN (1) IN2014DN05986A (es)
LT (3) LT2804851T (es)
MX (2) MX380943B (es)
MY (2) MY203015A (es)
NI (1) NI201400078A (es)
NL (1) NL301243I2 (es)
NO (1) NO2023038I1 (es)
NZ (2) NZ722400A (es)
PE (2) PE20190801A1 (es)
PH (3) PH12014501626B1 (es)
PL (2) PL2804851T3 (es)
PT (2) PT2804851T (es)
RS (2) RS62919B1 (es)
SG (3) SG10201608374XA (es)
SI (2) SI2804851T1 (es)
SM (2) SMT201800439T1 (es)
TW (2) TWI636040B (es)
UA (2) UA122324C2 (es)
WO (1) WO2013107291A1 (es)
ZA (1) ZA202100373B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
JP5856052B2 (ja) 2009-06-29 2016-02-09 アジオス ファーマシューティカルズ， インコーポレイテッド 治療化合物および組成物
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
PH12017501176B1 (en) 2011-05-03 2023-03-08 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
RS57401B1 (sr) 2012-01-06 2018-09-28 Agios Pharmaceuticals Inc Terapeutski aktivna jedinjenja i postupci za njihovu upotrebu
ES2698625T3 (es) * 2012-01-19 2019-02-05 Agios Pharmaceuticals Inc Compuestos terapéuticamente activos y sus métodos de uso
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
NZ706999A (en) 2012-10-15 2018-12-21 Agios Pharmaceuticals Inc Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JP6471155B2 (ja) 2013-07-11 2019-02-13 アギオス ファーマシューティカルス，インコーポレーテッド 癌の治療のためのｉｄｈ２変異体阻害剤としてのｎ，６−ビス（アリール又はヘテロアリール）−１，３，５−トリアジン−２，４−ジアミン化合物
AU2014287121B2 (en) 2013-07-11 2018-11-15 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015010297A1 (en) * 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) * 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN103694142A (zh) * 2013-11-28 2014-04-02 浙江科技学院 4-N-Boc-氨基环己酮的制备方法
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US9968595B2 (en) * 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
NZ723860A (en) * 2014-03-14 2023-04-28 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
CA2957046C (en) 2014-08-04 2022-11-15 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
SMT202000275T1 (it) 2014-10-01 2020-07-08 Daiichi Sankyo Co Ltd Derivato isossazolico come inibitore dell'isocitrato deidrogenasi 1 mutata
HUE063541T2 (hu) 2015-06-11 2024-01-28 Agios Pharmaceuticals Inc Eljárások piruvát-kináz aktivátorok alkalmazására
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
CN108697698B (zh) * 2015-10-15 2021-12-03 阿吉奥斯制药公司 用于治疗恶性肿瘤的组合疗法
IL258684B2 (en) * 2015-10-15 2023-04-01 Agios Pharmaceuticals Inc Combination therapy including an isocitrate dehydrogenase (1idh) inhibitor for use in the treatment of acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of 1idh
EA039805B1 (ru) * 2015-11-13 2022-03-15 Аджиос Фармасьютикалз, Инк. Комбинированная терапия для лечения злокачественных опухолей
US20200268726A1 (en) * 2015-12-04 2020-08-27 Agios Pharmaceuticals, Inc. Methods of treatment of malignancies
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
KR20180114202A (ko) * 2016-02-26 2018-10-17 아지오스 파마슈티컬스 아이엔씨. 혈액 악성종양 및 고형 종양의 치료를 위한 idh1 억제제
BR112018069504B1 (pt) * 2016-03-22 2023-12-26 Centaurus Biopharma Co., Ltd. Composto de sultam, uso do mesmo para tratar cânceres induzidos por mutação de idh1 e composição farmacêutica compreendendo dito composto
WO2018010142A1 (en) 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
UA125852C2 (uk) 2016-08-31 2022-06-22 Ле Лаборатуар Сервьє Інгібітори клітинних метаболічних процесів
CN119280245A (zh) 2017-06-12 2025-01-10 法国施维雅药厂 使用组合疗法治疗脑肿瘤的方法
CN111163776A (zh) * 2017-06-12 2020-05-15 安吉奥斯医药品有限公司 使用组合疗法治疗脑肿瘤的方法
CN111065630B (zh) * 2017-09-22 2022-12-30 正大天晴药业集团股份有限公司 一种内磺酰胺化合物结晶
WO2019104318A1 (en) * 2017-11-27 2019-05-31 Teva Pharmaceuticals Usa, Inc. Solid state forms of ivosidenib
WO2019161383A1 (en) * 2018-02-19 2019-08-22 The Regents Of The University Of Colorado, A Body Corporate Oxopiperidine quantitation by mass spectrometry
HUE061331T2 (hu) 2018-05-16 2023-06-28 Forma Therapeutics Inc Mutáns IDH-1 gátlása
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US10980788B2 (en) * 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN112367995A (zh) 2018-07-06 2021-02-12 安吉奥斯医药品有限公司 艾伏尼布形式和药物组合物
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN109535025B (zh) * 2018-12-18 2022-09-09 尚科生物医药（上海）有限公司 一种艾伏尼布中间体3,3-二氟环丁胺盐酸盐的制备方法
WO2020127887A1 (en) 2018-12-21 2020-06-25 Sandoz Ag Process for the preparation of an intermediate product of ivosidenib
GEP20247709B (en) 2019-08-08 2024-12-25 Servier Lab Method for preparing ivosidenib and an intermediate thereof
TW202120486A (zh) * 2019-08-09 2021-06-01 英商阿帝歐斯製藥有限公司 新穎化合物
EP4010080B1 (en) * 2019-08-09 2023-09-27 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer
US20220324838A1 (en) * 2019-08-09 2022-10-13 Alembic Pharmaceuticals Limited An Improved Process Of Preparation Of Ivosidenib
WO2021071678A1 (en) 2019-10-07 2021-04-15 University Hospitals Cleveland Medical Center Methods for treating wild type isocitrate dehydrogenase 1 cancers
WO2021079380A1 (en) * 2019-10-23 2021-04-29 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of (2s)-n-{(1s)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-n-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
TWI873212B (zh) * 2019-10-29 2025-02-21 大陸商上海翰森生物醫藥科技有限公司 四員環類衍生物調節劑、其製備方法和應用
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
WO2021124277A1 (en) 2019-12-20 2021-06-24 Nuevolution A/S Compounds active towards nuclear receptors
AU2021249530A1 (en) 2020-03-31 2022-12-01 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
CN111349081B (zh) * 2020-04-28 2021-01-15 宁波大学科学技术学院 一种Ivosidenib及其中间体的手性合成方法
AU2021311539A1 (en) 2020-07-21 2023-02-09 Daiichi Sankyo Company, Limited Combination drug of temozolomide and inhibitor of mutated IDH1 enzyme
CN116332905B (zh) * 2021-12-23 2025-07-08 上海翊石医药科技有限公司 (s)-n-苯基-1-(吡啶-2-基)吡咯烷-2-甲酰胺衍生物
US20250066368A1 (en) * 2021-12-30 2025-02-27 Shanghai Apeiron Therapeutics Company Limited Dna polymerase theta inhibitor and use thereof
CN117069618A (zh) * 2022-12-13 2023-11-17 常州制药厂有限公司 一种利用微通道反应器制备阿布西替尼关键中间体的方法
AR133410A1 (es) 2023-08-01 2025-09-24 Servier Lab Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo
CN117776955A (zh) * 2023-12-27 2024-03-29 苏州莱安医药化学技术有限公司 一种艾伏尼布及其中间体的合成方法

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
DE1252823B (es) 1963-02-15
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3867383A (en) 1971-03-29 1975-02-18 Ciba Geigy Corp Monoanthranilatoanilino-s-triazines
BE793501A (fr) 1971-12-31 1973-06-29 Ciba Geigy Composes heterocycliques et produits phytopharmaceutiques qui en contiennent
CH606334A5 (es) 1974-06-21 1978-10-31 Ciba Geigy Ag
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
US5041443A (en) 1989-02-21 1991-08-20 Dainippon Pharmaceutical Co., Ltd. Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof
DE69010232T2 (de) 1989-03-03 1994-12-01 Dainippon Pharmaceutical Co 2-(1-Piperazinyl)-4-phenylcycloalkanpyridin-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten.
JPH0491034A (ja) 1990-08-02 1992-03-24 Fujimoto Daiagunosuteitsukusu:Kk 中枢神経保護剤
JPH0499768A (ja) 1990-08-17 1992-03-31 Dainippon Pharmaceut Co Ltd ４―（４―フェニルピリジン―２―イル）ピペラジン―１―オキシド誘導体
JPH05140126A (ja) 1991-11-26 1993-06-08 Hokko Chem Ind Co Ltd トリアゾール誘導体および除草剤
AU665238B2 (en) 1992-02-28 1995-12-21 Zenyaku Kogyo Kabushiki Kaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
WO1998021191A1 (en) 1995-05-16 1998-05-22 Nissan Chemical Industries, Ltd. Cyanoethylmelamine derivatives and process for producing the same
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
EP0880501A1 (en) 1996-02-02 1998-12-02 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
CA2252501A1 (en) 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US6399358B1 (en) 1997-03-31 2002-06-04 Thomas Jefferson University Human gene encoding human chondroitin 6-sulfotransferase
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
PT1042305E (pt) 1997-12-22 2005-10-31 Bayer Pharmaceuticals Corp Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
AU9064598A (en) 1998-07-10 2000-02-01 Harald Groger Precusors for pna-monomers
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
DE69943205D1 (de) 1998-08-06 2011-03-31 Mountain View Pharmaceuticals Peg-uricase Konjugate und Verwendung davon
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
EP1187825A1 (en) 1999-06-07 2002-03-20 Shire Biochem Inc. Thiophene integrin inhibitors
NZ517426A (en) 1999-08-27 2004-04-30 Sugen Inc Phosphate mimics and methods of treatment using phosphatase inhibitors
JP4744050B2 (ja) 1999-09-17 2011-08-10 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ベンズアミドおよび関連するＸａ因子阻害剤
BR0014078A (pt) 1999-09-17 2002-12-31 Millennium Pharm Inc Inibidores de fator xa
IL150420A0 (en) 1999-12-28 2002-12-01 Pharmacopeia Inc Pyrimidine and triazine kinase inhibitors
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
JP2004525071A (ja) 2000-07-20 2004-08-19 ニューロジェン コーポレイション カプサイシン受容体リガンド
JP4113323B2 (ja) 2000-08-07 2008-07-09 富士フイルム株式会社 アゾ色素及びそれを含むインクジェット記録用インク、並びにインクジェット記録方法
US6525091B2 (en) 2001-03-07 2003-02-25 Telik, Inc. Substituted diarylureas as stimulators for Fas-mediated apoptosis
US20030095958A1 (en) 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
IL158590A0 (en) 2001-06-11 2004-05-12 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
ATE485281T1 (de) 2001-08-17 2010-11-15 Basf Se Triazinderivate und deren verwendung als sonnenschutzmittel
JP4753336B2 (ja) 2001-09-04 2011-08-24 日本化薬株式会社 新規アリル化合物及びその製法
US6878196B2 (en) 2002-01-15 2005-04-12 Fuji Photo Film Co., Ltd. Ink, ink jet recording method and azo compound
US20040067234A1 (en) 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
WO2004009562A1 (en) 2002-07-18 2004-01-29 Janssen Pharmaceutica, Nv Substituted triazine kinase inhibitors
JP2004083610A (ja) 2002-08-22 2004-03-18 Fuji Photo Film Co Ltd インクセット、インクカートリッジ、記録方法、プリンター及び記録物
JP2004107220A (ja) 2002-09-13 2004-04-08 Mitsubishi Pharma Corp ＴＮＦ−α産生抑制剤
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
AU2003293333A1 (en) 2002-12-02 2004-06-23 Arqule, Inc. Method of treating cancers
NZ541050A (en) 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
KR20050098244A (ko) 2003-01-10 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 2-데옥시글루코오스를 사용한 암 치료 방법
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
AU2004263148B2 (en) 2003-08-06 2008-08-21 Vertex Pharmaceuticals, Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
US7582645B2 (en) 2003-10-10 2009-09-01 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
JP4099768B2 (ja) 2003-11-10 2008-06-11 富士電機デバイステクノロジー株式会社 電子写真感光体および該電子写真感光体に起因する干渉縞有無の判定方法
WO2005060956A1 (en) 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
WO2005065691A1 (en) 2003-12-24 2005-07-21 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
JP2005264016A (ja) 2004-03-19 2005-09-29 Fuji Photo Film Co Ltd インクジェット記録用インク、インクセット及びインクジェット記録方法
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
GB0412526D0 (en) 2004-06-05 2004-07-14 Leuven K U Res & Dev Type 2 diabetes
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CA2581454A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
BRPI0606930A2 (pt) 2005-01-25 2009-12-01 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, métodos para a produção de um efeito de inibição de b-raf em um animal de sangue quente, para a produção de um efeito anti-cáncer em um animal de sangue quente e para o tratamento de doenças de um animal em um animal de sangue quente
KR101304289B1 (ko) 2005-04-11 2013-09-12 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
US8278038B2 (en) 2005-06-08 2012-10-02 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
CN101296909B (zh) 2005-08-26 2011-10-12 默克雪兰诺有限公司 吡嗪衍生物及其作为pi3k抑制剂的应用
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US20100297673A1 (en) 2006-09-20 2010-11-25 Reddy Us Therapeutics Methods and compositions for upregulation of peroxiredoxin activity
US20080109846A1 (en) 2006-10-23 2008-05-08 Ewertz C Christian System and method for audiovisual content playback
CA2669117A1 (en) 2006-10-26 2008-05-02 Gary A. Flynn Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
WO2008070661A1 (en) 2006-12-04 2008-06-12 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
EP2101760B1 (en) 2006-12-08 2013-02-27 Millennium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
JP5622393B2 (ja) 2006-12-15 2014-11-12 アブラクシスバイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
CA2684968C (en) 2007-04-30 2015-07-07 Prometic Biosciences Inc. Compounds, compositions containing such compounds, and methods of treatment of cancer and autoimmune diseases using such compounds
AU2008262291A1 (en) 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
CA2693901C (en) 2007-07-20 2015-12-29 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
ES2392003T3 (es) 2007-07-25 2012-12-03 Bristol-Myers Squibb Company Inhibidores de la triazina quinasa
TW200906818A (en) 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
AU2008311727A1 (en) 2007-10-10 2009-04-16 Takeda Pharmaceutical Company Limited Amide compound
WO2009051910A1 (en) * 2007-10-16 2009-04-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5277685B2 (ja) 2008-03-26 2013-08-28 富士ゼロックス株式会社 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
CN101575408B (zh) 2008-05-09 2013-10-30 Mca技术有限公司 用作阻燃剂和光稳定剂的聚三嗪基化合物
EP4327888A3 (en) 2008-05-15 2024-05-22 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
FR2932483A1 (fr) 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
WO2010007756A1 (ja) 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
WO2010028099A1 (en) 2008-09-03 2010-03-11 The Johns Hopkins University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
WO2010028179A1 (en) 2008-09-03 2010-03-11 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds as gata modulators
JP2010079130A (ja) 2008-09-29 2010-04-08 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
EP2370417A2 (en) 2008-11-21 2011-10-05 Millennium Pharmaceuticals, Inc. Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
JP2010181540A (ja) 2009-02-04 2010-08-19 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
AU2010211672B2 (en) 2009-02-06 2016-08-04 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
WO2010129596A1 (en) 2009-05-04 2010-11-11 Agios Pharmaceuticals, Inc. Pmk2 modulators for use in the treatment of cancer
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
EP2440050A4 (en) 2009-06-08 2013-04-03 California Capital Equity Llc TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
EP2440056A4 (en) 2009-06-09 2012-12-05 California Capital Equity Llc DERIVATIVES OF UREIDOPHENYL SUBSTITUTED TRIAZINE AND THERAPEUTIC APPLICATIONS THEREOF
KR20120026611A (ko) 2009-06-09 2012-03-19 아브락시스 바이오사이언스, 엘엘씨 헷지호그 신호전달의 피리딜-트리아진 억제제
JP5856052B2 (ja) 2009-06-29 2016-02-09 アジオス ファーマシューティカルズ， インコーポレイテッド 治療化合物および組成物
EP2451402B1 (en) 2009-07-10 2016-04-27 Kirk Promotion LTD. Knee joint device
WO2011027249A2 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
CA2773561A1 (en) 2009-09-14 2011-03-17 Phusis Therapeutics Inc. Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
JP5473851B2 (ja) 2009-09-30 2014-04-16 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置
US8652534B2 (en) 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
CN105153188B (zh) 2009-10-22 2018-06-01 法博太科制药有限公司 抗纤维化剂的稠环类似物
ES2642109T3 (es) 2009-12-09 2017-11-15 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
NZ578968A (en) 2010-02-10 2011-03-31 Allans Sheetmetal And Engineering Services Fuel feed system for a pellet fire
EP2553116A4 (en) 2010-04-01 2013-10-23 Agios Pharmaceuticals Inc METHOD FOR IDENTIFYING A CANDIDATE COMPOUND
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
CN103097340B (zh) 2010-07-16 2018-03-16 安吉奥斯医药品有限公司 治疗活性组合物及其使用方法
SG10201710578TA (en) 2010-10-21 2018-02-27 Medivation Technologies Inc Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
WO2012078288A2 (en) 2010-11-08 2012-06-14 Washington University Methods of determining risk of adverse outcomes in acute myeloid leukemia
BR112013013429A2 (pt) 2010-11-29 2017-03-21 Galleon Pharmaceuticals Inc composição, método de prevenção ou tratamento de distúrbio ou doença de controle da respiração, e, método de prevenção de desestabilização ou estabilização do ritmo respiratório
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
EP2691391A4 (en) 2011-03-29 2014-09-10 Broad Inst Inc COMPOUNDS AND METHODS OF TREATING DISORDERS MEDIATED BY ISOCITRATE DEHYDROGENASE
CN103608016A (zh) 2011-05-03 2014-02-26 安吉奥斯医药品有限公司 丙酮酸激酶激活剂在治疗中的用途
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
JP2014522242A (ja) 2011-06-06 2014-09-04 メルク・シャープ・アンド・ドーム・コーポレーション イソクエン酸デヒドロゲナーゼ（ｉｄｈ１）遺伝子発現のｒｎａ干渉媒介抑制
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
ES2698847T3 (es) 2011-07-07 2019-02-06 Merck Patent Gmbh Azaheterociclos sustituidos para el tratamiento del cáncer
ES2627120T3 (es) 2011-07-08 2017-07-26 Helmholtz-Zentrum für Infektionsforschung GmbH Medicamento para el tratamiento del cáncer de hígado
EP2734519B1 (en) 2011-07-22 2016-05-04 University Of Louisville Research Foundation, Inc. Anti-biofilm compounds
GEP20166432B (en) 2011-09-27 2016-02-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CN102659765B (zh) 2011-12-31 2014-09-10 沈阳药科大学 嘧啶及三嗪类化合物的制备方法和应用
RS57401B1 (sr) 2012-01-06 2018-09-28 Agios Pharmaceuticals Inc Terapeutski aktivna jedinjenja i postupci za njihovu upotrebu
ES2698625T3 (es) 2012-01-19 2019-02-05 Agios Pharmaceuticals Inc Compuestos terapéuticamente activos y sus métodos de uso
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
EP2634259A1 (en) 2012-03-01 2013-09-04 Deutsches Krebsforschungszentrum Means and methods for the determination of (D)-2-hydroxyglutarate (D2HG)
WO2013133367A1 (ja) 2012-03-09 2013-09-12 カルナバイオサイエンス株式会社 新規トリアジン誘導体
WO2014015422A1 (en) 2012-07-27 2014-01-30 Ontario Institute For Cancer Research Cellulose-based nanoparticles for drug delivery
NZ706999A (en) 2012-10-15 2018-12-21 Agios Pharmaceuticals Inc Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015127173A1 (en) 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
NZ723860A (en) 2014-03-14 2023-04-28 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
IL258684B2 (en) 2015-10-15 2023-04-01 Agios Pharmaceuticals Inc Combination therapy including an isocitrate dehydrogenase (1idh) inhibitor for use in the treatment of acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of 1idh
CN108697698B (zh) 2015-10-15 2021-12-03 阿吉奥斯制药公司 用于治疗恶性肿瘤的组合疗法
US20200268726A1 (en) 2015-12-04 2020-08-27 Agios Pharmaceuticals, Inc. Methods of treatment of malignancies
KR20180114202A (ko) 2016-02-26 2018-10-17 아지오스 파마슈티컬스 아이엔씨. 혈액 악성종양 및 고형 종양의 치료를 위한 idh1 억제제

Also Published As

Publication number Publication date
NZ722400A (en) 2018-02-23
KR102144739B1 (ko) 2020-08-18
SG11201404190PA (en) 2014-08-28
PL3447052T3 (pl) 2022-05-09
CY2023023I1 (el) 2024-02-16
PH12017501419A1 (en) 2018-10-08
UA115047C2 (uk) 2017-09-11
CN104136411B (zh) 2016-10-12
CA2861556C (en) 2021-07-13
EP3985001A1 (en) 2022-04-20
US9474779B2 (en) 2016-10-25
EP3447052A1 (en) 2019-02-27
HUE057264T2 (hu) 2022-05-28
FR23C1031I1 (fr) 2023-10-13
LTPA2023529I1 (es) 2023-10-25
SG10202103521PA (en) 2021-05-28
US20190315802A1 (en) 2019-10-17
IL264516A (en) 2019-02-28
CN106496090A (zh) 2017-03-15
ES2685746T3 (es) 2018-10-11
TW201331177A (zh) 2013-08-01
HK1198439A1 (en) 2015-04-24
KR102108507B1 (ko) 2020-05-08
US20240059733A1 (en) 2024-02-22
HRP20220017T1 (hr) 2022-04-01
AR089768A1 (es) 2014-09-17
JP2019031562A (ja) 2019-02-28
BR112014017840B1 (pt) 2023-01-17
JP6805220B2 (ja) 2020-12-23
EA035662B1 (ru) 2020-07-23
CY1124988T1 (el) 2023-01-05
EP2804851B1 (en) 2018-07-18
IN2014DN05986A (es) 2015-06-26
AR122902A2 (es) 2022-10-12
LT2804851T (lt) 2018-09-10
MX351166B (es) 2017-10-04
ZA202100373B (en) 2023-04-26
BR112014017840A2 (es) 2017-06-20
HRP20181199T1 (hr) 2018-11-16
EA201692271A1 (ru) 2018-01-31
JP2017101067A (ja) 2017-06-08
NZ627053A (en) 2017-01-27
SI2804851T1 (sl) 2018-11-30
HUS2300035I1 (hu) 2024-07-28
MY203015A (en) 2024-06-04
JP2021038263A (ja) 2021-03-11
PH12018501410A1 (en) 2019-08-14
US10640534B2 (en) 2020-05-05
EP2804851A4 (en) 2015-06-24
RS62919B1 (sr) 2022-03-31
TWI636040B (zh) 2018-09-21
EA026723B1 (ru) 2017-05-31
SMT201800439T1 (it) 2018-09-13
KR20190128747A (ko) 2019-11-18
SG10201608374XA (en) 2016-12-29
NL301243I2 (nl) 2023-10-04
CR20170097A (es) 2017-06-30
FIC20230031I1 (fi) 2023-10-10
TWI713847B (zh) 2020-12-21
WO2013107291A1 (en) 2013-07-25
PH12017501419B1 (en) 2022-02-02
AU2013211436A1 (en) 2014-07-24
CL2014001891A1 (es) 2014-11-14
PT3447052T (pt) 2022-01-18
FR23C1031I2 (fr) 2024-08-16
JP2015509098A (ja) 2015-03-26
PE20141824A1 (es) 2014-12-11
US20160130298A1 (en) 2016-05-12
EP2804851A1 (en) 2014-11-26
AU2013211436B2 (en) 2017-08-24
CO7010834A2 (es) 2014-07-31
MX2014008744A (es) 2014-08-29
NI201400078A (es) 2014-10-10
CN106496090B (zh) 2020-04-21
AU2019283951A1 (en) 2020-01-23
LTC2804851I2 (es) 2025-06-10
PT2804851T (pt) 2018-10-15
KR20200049913A (ko) 2020-05-08
SMT202200027T1 (it) 2022-05-12
MY178486A (en) 2020-10-14
KR102044730B1 (ko) 2019-11-15
IL233683B (en) 2019-02-28
ES2903390T3 (es) 2022-04-01
ECSP14014544A (es) 2015-12-31
HUE039110T2 (hu) 2018-12-28
EP3447052B1 (en) 2021-10-20
US10717764B2 (en) 2020-07-21
US20180194802A1 (en) 2018-07-12
DK2804851T3 (en) 2018-09-03
IL281942A (en) 2021-05-31
CA3077245A1 (en) 2013-07-25
PH12014501626A1 (en) 2014-10-13
AU2017265100B2 (en) 2019-10-03
KR20140127255A (ko) 2014-11-03
UA122324C2 (uk) 2020-10-26
BR112014017840A8 (pt) 2017-07-11
CR20140388A (es) 2014-11-13
PL2804851T3 (pl) 2018-11-30
US11667673B2 (en) 2023-06-06
LT3447052T (lt) 2022-02-10
CY1120651T1 (el) 2019-12-11
IL264516B (en) 2021-04-29
US9850277B2 (en) 2017-12-26
RS57730B1 (sr) 2018-12-31
MX380943B (es) 2025-03-10
PH12014501626B1 (en) 2018-08-31
IL233683A0 (en) 2014-09-30
DK3447052T3 (da) 2022-01-17
TW201843136A (zh) 2018-12-16
CA2861556A1 (en) 2013-07-25
SI3447052T1 (sl) 2022-04-29
NO2023038I1 (no) 2023-10-13
JP6313714B2 (ja) 2018-04-18
AU2019283951B2 (en) 2021-05-13
IL281942B (en) 2022-03-01
US20130190249A1 (en) 2013-07-25
AU2017265100A1 (en) 2017-12-14
US20170015703A1 (en) 2017-01-19
US20210024575A1 (en) 2021-01-28
CN104136411A (zh) 2014-11-05
EA201491391A1 (ru) 2014-10-30

Similar Documents

Publication Publication Date Title
PE20190801A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
MY170922A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
CA2875877C (en) Syk inhibitors
EP2288260A4 (en) TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
MX2014002208A (es) Inhibidores de serina/treonina quinasa.
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
MX361652B (es) Análogos de cortistatina y síntesis y usos de los mismos.
PE20200387A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
NZ706775A (en) Methylene linked quinolinyl modulators of ror-gamma-t
CR20150254A (es) Compuestos quimicos
PH12017500048A1 (en) Pyridone derivative having tetrahydropyranylmethyl group
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
ES2570385T3 (es) N-(1H-pirazolil-metil)-formamidas, procedimiento para su producción y su uso como inhibidores de la nitrificación
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
NZ701894A (en) Dimethyl-benzoic acid compounds
AR075951A1 (es) Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek
PE20151754A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
EA201490754A1 (ru) Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора
UY33149A (es) Compuestos carboxamida y su uso como inhibidores iv de calpaina
PE20160855A1 (es) Quinazolin-thf-aminas como inhibidores de pde1
MY184561A (en) Substituted pyrimidine compounds and their use as syk inhibitors
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
BR112015006370A8 (pt) composto citotóxico, sua mistura e sal farmaceuticamente aceitável, sal/solvente complexo, metal complexo, exceto um com qualquer de fe2+, fer+, co2+, complexo solvente ou pró-fármico, bem como seu uso e composição o compreendendo
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal